Bo Liu , Minglu Wang , Ning Pu , Jiale Wang , Wenhui Fan , Chengkang Qu , Hao Wu , Zongming Song , Ye Tao
{"title":"揭示组蛋白去乙酰化酶抑制剂在对抗年龄相关视网膜退行性疾病中的潜力。","authors":"Bo Liu , Minglu Wang , Ning Pu , Jiale Wang , Wenhui Fan , Chengkang Qu , Hao Wu , Zongming Song , Ye Tao","doi":"10.1016/j.arr.2025.102788","DOIUrl":null,"url":null,"abstract":"<div><div>Retinal degeneration (RD), a group of progressive diseases marked by the loss of retinal neurons. Aging contributes to the gradual decline in cellular function, which, in turn, exacerbates the pathogenesis of RD through complex molecular mechanisms, including aberrant gene expression, impaired cellular signaling pathways, oxidative stress, and inflammation. The pivotal role of epigenetic histone modifications in mediating the onset and progression of neurological disorders has garnered increasing attention, especially concerning histone acetylation. The level of histone acetylation is regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs). HATs and HDACs can enzymatically modify lysine residues on histones or non-histones via adding or removing acetyl groups, leading to changes in transcriptional activity. Histone deacetylase inhibitors (HDACis) can interfere with the deacetylase activity of HDACs, enhance the level of both histone and non-histone acetylation, and exert a regulatory influence on gene transcription. Accumulating evidence supports the role of HDACis in the treatment of multiple medical conditions beyond cancer, renewing interest in their potential applications in age-related diseases. In this context, HDAC inhibition represents a novel approach for mitigating the age-related cellular dysfunctions contributing to RD. HDACis hold promise in addressing these pathological processes and preserving retinal function through targeting HDACs. We intend to elucidate the neuroprotective effects of common HDACis on age-related RD, with a focus on their role in counteracting the detrimental effects of aging, and provide a comprehensive summary of the efficacy of HDACis in both animal models and clinical trials for age-related RD. These findings would enrich our understanding of HDACis and promote their future applications in the treatment of age-related RD.</div></div>","PeriodicalId":55545,"journal":{"name":"Ageing Research Reviews","volume":"110 ","pages":"Article 102788"},"PeriodicalIF":12.4000,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Unlocking the potential of histone deacetylase inhibitors in combatting age-related retinal degenerative diseases\",\"authors\":\"Bo Liu , Minglu Wang , Ning Pu , Jiale Wang , Wenhui Fan , Chengkang Qu , Hao Wu , Zongming Song , Ye Tao\",\"doi\":\"10.1016/j.arr.2025.102788\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Retinal degeneration (RD), a group of progressive diseases marked by the loss of retinal neurons. Aging contributes to the gradual decline in cellular function, which, in turn, exacerbates the pathogenesis of RD through complex molecular mechanisms, including aberrant gene expression, impaired cellular signaling pathways, oxidative stress, and inflammation. The pivotal role of epigenetic histone modifications in mediating the onset and progression of neurological disorders has garnered increasing attention, especially concerning histone acetylation. The level of histone acetylation is regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs). HATs and HDACs can enzymatically modify lysine residues on histones or non-histones via adding or removing acetyl groups, leading to changes in transcriptional activity. Histone deacetylase inhibitors (HDACis) can interfere with the deacetylase activity of HDACs, enhance the level of both histone and non-histone acetylation, and exert a regulatory influence on gene transcription. Accumulating evidence supports the role of HDACis in the treatment of multiple medical conditions beyond cancer, renewing interest in their potential applications in age-related diseases. In this context, HDAC inhibition represents a novel approach for mitigating the age-related cellular dysfunctions contributing to RD. HDACis hold promise in addressing these pathological processes and preserving retinal function through targeting HDACs. We intend to elucidate the neuroprotective effects of common HDACis on age-related RD, with a focus on their role in counteracting the detrimental effects of aging, and provide a comprehensive summary of the efficacy of HDACis in both animal models and clinical trials for age-related RD. These findings would enrich our understanding of HDACis and promote their future applications in the treatment of age-related RD.</div></div>\",\"PeriodicalId\":55545,\"journal\":{\"name\":\"Ageing Research Reviews\",\"volume\":\"110 \",\"pages\":\"Article 102788\"},\"PeriodicalIF\":12.4000,\"publicationDate\":\"2025-05-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ageing Research Reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1568163725001345\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ageing Research Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1568163725001345","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
Unlocking the potential of histone deacetylase inhibitors in combatting age-related retinal degenerative diseases
Retinal degeneration (RD), a group of progressive diseases marked by the loss of retinal neurons. Aging contributes to the gradual decline in cellular function, which, in turn, exacerbates the pathogenesis of RD through complex molecular mechanisms, including aberrant gene expression, impaired cellular signaling pathways, oxidative stress, and inflammation. The pivotal role of epigenetic histone modifications in mediating the onset and progression of neurological disorders has garnered increasing attention, especially concerning histone acetylation. The level of histone acetylation is regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs). HATs and HDACs can enzymatically modify lysine residues on histones or non-histones via adding or removing acetyl groups, leading to changes in transcriptional activity. Histone deacetylase inhibitors (HDACis) can interfere with the deacetylase activity of HDACs, enhance the level of both histone and non-histone acetylation, and exert a regulatory influence on gene transcription. Accumulating evidence supports the role of HDACis in the treatment of multiple medical conditions beyond cancer, renewing interest in their potential applications in age-related diseases. In this context, HDAC inhibition represents a novel approach for mitigating the age-related cellular dysfunctions contributing to RD. HDACis hold promise in addressing these pathological processes and preserving retinal function through targeting HDACs. We intend to elucidate the neuroprotective effects of common HDACis on age-related RD, with a focus on their role in counteracting the detrimental effects of aging, and provide a comprehensive summary of the efficacy of HDACis in both animal models and clinical trials for age-related RD. These findings would enrich our understanding of HDACis and promote their future applications in the treatment of age-related RD.
期刊介绍:
With the rise in average human life expectancy, the impact of ageing and age-related diseases on our society has become increasingly significant. Ageing research is now a focal point for numerous laboratories, encompassing leaders in genetics, molecular and cellular biology, biochemistry, and behavior. Ageing Research Reviews (ARR) serves as a cornerstone in this field, addressing emerging trends.
ARR aims to fill a substantial gap by providing critical reviews and viewpoints on evolving discoveries concerning the mechanisms of ageing and age-related diseases. The rapid progress in understanding the mechanisms controlling cellular proliferation, differentiation, and survival is unveiling new insights into the regulation of ageing. From telomerase to stem cells, and from energy to oxyradical metabolism, we are witnessing an exciting era in the multidisciplinary field of ageing research.
The journal explores the cellular and molecular foundations of interventions that extend lifespan, such as caloric restriction. It identifies the underpinnings of manipulations that extend lifespan, shedding light on novel approaches for preventing age-related diseases. ARR publishes articles on focused topics selected from the expansive field of ageing research, with a particular emphasis on the cellular and molecular mechanisms of the aging process. This includes age-related diseases like cancer, cardiovascular disease, diabetes, and neurodegenerative disorders. The journal also covers applications of basic ageing research to lifespan extension and disease prevention, offering a comprehensive platform for advancing our understanding of this critical field.